Summary
Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y
RDY posts flat Q3 earnings, while revenues miss estimates as global generics growth lagged, pressured by weaker North America sales.
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript
3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape
Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.
ReadyTech Holdings Limited (RDY) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has ReadyTech Holdings Limited ever had a stock split?
ReadyTech Holdings Limited Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Erez Israeli CEO | CXA Exchange | US2561352038 ISIN |
| IN Country | 27,048 Employees | 25 Jul 2025 Last Dividend | 7 Sep 2006 Last Split | 11 Apr 2001 IPO Date |
Overview
Dr. Reddy's Laboratories Limited represents a multifaceted pharmaceutical entity with a global footprint, engaging in an integrated range of pharmaceutical activities. Established in 1984 and based in Hyderabad, India, the company maintains a broad operation spectrum through its distinct segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others. These segments underline the company's diversified approach, encompassing the production and marketing of generic and branded pharmaceutical products, active pharmaceutical ingredients (APIs), and contract research services, along with a focused effort on developing therapies in oncology and inflammation. Their commitment to innovation and quality places them among the leading pharmaceutical companies worldwide.
Products and Services
- Global Generics
This segment is pivotal in manufacturing and marketing prescription and over-the-counter pharmaceutical products, available both under brand names and as generic formulations equivalent to branded counterparts. Dr. Reddy’s has made significant strides in the biologics domain under this segment, indicating a strong emphasis on advancing therapeutic solutions and accessibility.
- Pharmaceutical Services and Active Ingredients (PSAI)
A crucial arm of Dr. Reddy’s, the PSAI segment is responsible for the manufacturing and marketing of active pharmaceutical ingredients and intermediates – the essential components for finishing pharmaceutical products. Notably, it extends contract research services, catering to the diverse requirements of customers by providing custom synthesized APIs and steroids. This segment underscores the company’s role as a vital player in the pharmaceutical value chain, bolstering the global supply of key pharmaceutical ingredients.
- Others
Under this segment, Dr. Reddy's delineates its focus on the research and development department, particularly in crafting therapies for oncology and inflammation. Additionally, it embarks on the development of differentiated formulations aimed at enhancing therapeutic efficacy and patient compliance. Another noteworthy area within this segment is their investment in digital healthcare solutions and IT-enabled business support services, demonstrating a forward-looking approach to adapting in an increasingly digitalized healthcare landscape.
